Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 18,411 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Female Clear all
Not listed Phase 1 Interventional

The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors

NCT04768868
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
IMP7068
Drug
Lead sponsor
Impact Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Atlanta, Georgia • Fairway, Kansas • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

NCT04707768
View directory record Official record
Conditions
Anemia Associated With Chronic Kidney Disease (CKD)
Interventions
Vadadustat, Mircera®
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
58
States / cities
Huntsville, Alabama • Phoenix, Arizona • Pine Bluff, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 30, 2026, 4:06 PM EDT
Active, not recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Sacituzumab tirumotecan, Doxorubicin, Paclitaxel, Nab-paclitaxel, Rescue medications
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
43
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Not applicable Interventional

VeSpAR: Comparing Vessel-Sparing Anastomotic Repair and Transecting Anastomotic Repair in Isolated Short Bulbar Strictures.

NCT03572348
View directory record Official record
Conditions
Urethral Stricture, Surgery, Urologic Diseases
Interventions
Transecting anastomotic repair (tAR), Vessel-sparing anastomotic repair (vsAR)
Procedure
Lead sponsor
University Hospital, Ghent
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Syracuse, New York • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Not applicable Interventional

Kangaroo Care and Premature Infant Sleep

NCT02473055
View directory record Official record
Conditions
Premature Birth of Newborn
Interventions
Kangaroo Care
Other
Lead sponsor
Case Western Reserve University
Other
Eligibility
7 Days to 37 Weeks
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Oct 30, 2026, 4:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Calcium Absorption in Postmenopausal Thai Women

NCT02291315
View directory record Official record
Conditions
Fractional Calcium Absorption
Interventions
Not listed
Lead sponsor
Cornell University
Other
Eligibility
53 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2014 · Synced Oct 30, 2026, 4:06 PM EDT
Terminated Phase 2 Interventional Results available

Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma

NCT00414076
View directory record Official record
Conditions
Leiomyosarcoma, Uterine Neoplasm
Interventions
Letrozole
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

NCT02988817
View directory record Official record
Conditions
Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Non Small Cell Lung Cancer (NSCLC), Thyroid Cancer, Melanoma, Sarcoma, Solid Tumors
Interventions
Enapotamab vedotin (HuMax-AXL-ADC)
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
20
States / cities
Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects

NCT02022748
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
ticagrelor
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 30, 2026, 4:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Transcriptomic Evaluation of Endometrial Receptivity

NCT04141085
View directory record Official record
Conditions
Infertility, Female
Interventions
Endometrial biopsy
Other
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects

NCT02078440
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Bromocriptine mesylate
Drug
Lead sponsor
VeroScience
Industry
Eligibility
10 Years to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Phoenix, Arizona • New Haven, Connecticut • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Oct 30, 2026, 4:06 PM EDT
Not listed Phase 3 Interventional

Preventing Acute Kidney Injury (AKI) in Pediatric Patients

NCT03897335
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Not applicable Interventional

Nurtured in Nature

NCT04146025
View directory record Official record
Conditions
Postpartum Depression, Pregnancy Related, Environmental Exposure
Interventions
Nature Coach Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Phase 1Phase 2 Interventional

Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment

NCT03672240
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Cancer (NMIBC)
Interventions
APL-1202
Drug
Lead sponsor
Asieris Pharmaceutical Technologies Co., Ltd.
Industry
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
New York, New York • Myrtle Beach, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 30, 2026, 4:06 PM EDT
Recruiting Phase 1 Interventional

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

NCT06483048
View directory record Official record
Conditions
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Carcinosarcoma, Recurrent Female Reproductive System Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Carcinosarcoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Carcinosarcoma, Refractory Fallopian Tube Carcinoma, Refractory Female Reproductive System Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
Interventions
Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
Biological · Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 30, 2026, 4:06 PM EDT
Terminated Not applicable Interventional

A Non-Invasive Cervical Cancer Screening Modality: A Pilot Study

NCT02767726
View directory record Official record
Conditions
Women With Abnormal Pap Smears
Interventions
non-invasive multimodal imaging
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 30, 2026, 4:06 PM EDT
Terminated Phase 1 Interventional Results available

Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

NCT02948426
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions
Autologous Monocytes + ACTIMMUNE + SYLATRON
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Circadian Rhythm Modulation by Dietary Phosphorus in Chronic Kidney Disease

NCT01341678
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Lanthanum Carbonate, NeutraPhos, Diet Only
Drug · Dietary Supplement · Other
Lead sponsor
Geoffrey Block
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Not applicable Interventional

Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women

NCT07408115
View directory record Official record
Conditions
Hot Flashes, Hot Flash, Hot Flushes, Menopause, Postmenopause, Hot Flushes and/or Sweats, Hot Flushes, Night Sweats, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms Associated With Menopause
Interventions
JDS-HF3.0
Dietary Supplement
Lead sponsor
Bonafide Health
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Harrison, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Phase 1 Interventional

Double Blind Randomized Placebo Controlled Trial of FOSTRAP Chewing Gum in Patients With CKD and Hyperphosphatemia

NCT01057108
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease
Interventions
FOSTRAP Chewing Gum, Placebo chewing gum
Other
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 7, 2011 · Synced Oct 30, 2026, 4:06 PM EDT
Terminated Phase 3 Interventional Results available

Empiric Therapy of Mucopurulent Cervicitis (MPC)

NCT01072136
View directory record Official record
Conditions
Vaginitis Bacterial, Cervicitis
Interventions
Placebo, Azithromycin, Cefixime
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Birmingham, Alabama • Torrance, California • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 30, 2026, 4:06 PM EDT
Terminated Not applicable Interventional

Women In Steady Exercise Research - Window of Opportunity for Exercise and Tumor Biology

NCT05428709
View directory record Official record
Conditions
Breast Cancer
Interventions
Acute Exercise
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 30, 2026, 4:06 PM EDT
Completed Not applicable Interventional

Remote Ischemic Preconditioning for Renal Protection in TAVI

NCT03347032
View directory record Official record
Conditions
Aortic Valve Stenosis, Renal Insufficiency, Contrast-induced Nephropathy
Interventions
Remote ischemic preconditioning, Control
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 30, 2026, 4:06 PM EDT
No Longer Available No phase listed Expanded access

131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

NCT05064306
View directory record Official record
Conditions
Central Nervous System/Leptomeningeal Neoplasms
Interventions
131I-omburtamab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 30, 2026, 4:06 PM EDT